Examines oncologic outcomes in high-risk colorectal liver metastases treated with neoadjuvant CAPOX and bevacizumab, suggesting its effectiveness.
Key Points
The research aims to assess the safety and efficacy of short-course neoadjuvant therapy using CAPOX and bevacizumab in patients with high-risk colorectal liver metastases.
Included patients with synchronous or metachronous colorectal liver metastases (CRLM)
Administered two cycles of neoadjuvant CAPOX plus bevacizumab
Conducted biochemical, radiologic, and pathologic response assessments
Analyzed survival outcomes and treatment tolerability
57 patients included, with 65% having synchronous disease
53.7% achieved over 50% reduction in tumor markers
Partial response observed in 31.6% and complete response in 1.7% of cases
Grade ≥3 adverse events occurred in 10.6% of patients, mainly neutropenia and diarrhea
Improved overall survival and recurrence-free survival in patients with tumors <5 cm and those receiving adjuvant therapy